Hepatitis C
Newsletter
October 2012
Clinical
Trials, Cohort Studies, Pilot Studies
Vitamin D
and the racial difference in the genotype 1 chronic hepatitis C treatment
response.
Weintraub SJ, Fleckenstein JF,
Marion TN, et al. Am J Clin Nutr.
2012 Sep 26. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/23015322
African Americans are less likely
to have clearance of hepatitis C virus infection: the findings from recent u.s. Population data. Mir HM, Stepanova M, Afendy
M, Kugelmas M, Younossi ZM. J Clin Gastroenterol.
2012 Sep;46(8):e62-5.
http://www.ncbi.nlm.nih.gov/pubmed/22178959
Perceived
Barriers to Hepatitis C Therapy for Patients Receiving Opioid Agonist
Treatment.
Zickmund SL, Campbell SA, Tirado
CF, Zook CL, Weinrieb RM. J
Addict Med. 2012 Sep;6(3):233-239.
http://www.ncbi.nlm.nih.gov/pubmed/22790464
Single-dose
pharmacokinetics of boceprevir in subjects with
impaired hepatic or renal function. Treitel M, Marbury T, Preston RA, et al. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi:
10.2165/11633440-000000000-00000.
http://www.ncbi.nlm.nih.gov/pubmed/22799589
Combination of fluvastatin with pegylated
interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C
infected with HCV genotype 1b. Atsukawa M, Tsubota A, Kondo C, et al. J Gastroenterol
Hepatol. 2012 Sep 18. doi:
10.1111/j.1440-1746.2012.07267.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22989264
IL28B polymorphism as a predictor
of antiviral response in chronic hepatitis C. Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz
I, et al. Głowacki MK, Owczarek
D, Cibor D, Sanak M, Mach
T.
http://www.ncbi.nlm.nih.gov/pubmed/23002361
Baseline characteristics and
mortality among people in care for chronic viral hepatitis: The Chronic
Hepatitis Cohort Study (CHeCS). Moorman
AC, Gordon SC, Rupp LB, Spradling PR, et al. . Clin Infect Dis. 2012 Sep 18.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22990852
Quantifying
the fraction of cirrhosis attributable to alcohol among chronic HCV patients:
Implications for treatment cost-effectiveness. Innes
HA, Hutchinson SJ, Barclay S, et al. Hepatology. 2012 Sep 7. doi:
10.1002/hep.26051. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22961861
Variability of hepatitis C virus hypervariable
region 1 (HVR-1) during the early phase of pegylated
interferon and ribavirin therapy. Caraballo CK, Laskus
T, Bukowska-Ośko I, et al. Adv
Med Sci. 2012 Sep 11:1-5. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22968340
Basic
and Applied Science, Pre-Clinical Studies
Association of enhanced activity
of indoleamine 2,3-dioxygenase
in dendritic cells with the induction of regulatory T cells in chronic
hepatitis C infection. Higashitani K,
Kanto T, Kuroda S, et al. J Gastroenterol. 2012 Sep 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22976933
Increase
in platelet count based on inosine triphosphatase genotype during interferon beta plus
ribavirin combination therapy. Nomura
H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki
N, Mizokami M. J Gastroenterol
Hepatol. 2012 Sep;27(9):1461-6.
doi:
10.1111/j.1440-1746.2012.07171.x.
http://www.ncbi.nlm.nih.gov/pubmed/22554247
Hepatitis
C virus NS3/4A protease blocks IL-28 production. Ding Q, Huang B, Lu J, Liu YJ, Zhong J. Eur J Immunol. 2012 Sep;42(9):2374-82. doi: 10.1002/eji.201242388.
http://www.ncbi.nlm.nih.gov/pubmed/22685015
CD4(+)
and CD8(+) Regulatory T Cells (Tregs) are Elevated
and Display an Active Phenotype in Patients with Chronic HCV Mono-Infection and
HIV/HCV Co-Infection.
Hartling HJ, Gaardbo
JC, Ronit A, et al. Scand J
Immunol. 2012 Sep;76(3):294-305.
doi: 10.1111/j.1365-3083.2012.02725.x.
http://www.ncbi.nlm.nih.gov/pubmed/22671952
Towards
a Hepatitis C Vaccine: the Structural Basis of Hepatitis C Virus Neutralization
by AP33, a Broadly Neutralizing Antibody. Potter JA, Owsianka AM,
Jeffery N, et al. J Virol. 2012 Sep
19. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22993159
Regulation of hepatitis C virus replication and gene
expression by the MAPK-ERK pathway. Pei R, Zhang X, Xu S, Meng Z, Roggendorf
M, Lu M, Chen X. Virol Sin. 2012
Sep 21. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/23001481
HIV/HCV
Coinfection
Response to raltegravir-based salvage therapy in HIV-infected patients
with hepatitis C virus or hepatitis B virus coinfection. Weimer
LE, Fragola V, Floridia M, et
al. J Antimicrob Chemother.
2012 Sep 14. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22984206
Buprenorphine for Human
Immunodeficiency Virus/Hepatitis C Virus-coinfected
Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy? Taylor
LE, Maynard MA, Friedmann PD, et al. J Addict Med.
2012 Sep;6(3):179-85.
http://www.ncbi.nlm.nih.gov/pubmed/22614935
Atazanavir-based antiretroviral therapy is
associated with higher hepatitis C virus viral load in HIV/hepatitis C virus
patients. Rivero-Juarez A, Mira JA, Santos I, et al. AIDS Res Hum Retroviruses. 2012 Sep 11. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22966845
The influence of hepatitis B
virus on antiviral treatment with interferon and ribavirin in Asian patients
with hepatitis C virus/hepatitis B virus coinfection:
a meta-analysis. Liu JY, Sheng YJ, Hu HD, et al. Virol
J. 2012 Sep 6;9(1):186. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22950520
A prospective evaluation of
pulmonary, systemic and hepatic hemodynamics in HIV-HCV coinfected
patients prior and after antiviral therapy with pegylated
interferon and ribavirin. Reiberger T,
Payer BA, Ferlitsch A, et al. Antivir
Ther. 2012 Sep 5. doi: 10.3851/IMP2349. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22948263
Human
immunodeficiency virus enhances hepatitis C virus replication by differential
regulation of IFN and TGF family genes. Zhang X, Daucher M, Baeza J, Kim CW, Russell R, Kottilil
S. J Med Virol. 2012 Sep;84(9):1344-52.
doi: 10.1002/jmv.23315.
http://www.ncbi.nlm.nih.gov/pubmed/22825812
Epidemiology,
Diagnostics, and Miscellaneous Works
Chronic Pain Treatment and Health Service
Utilization of Veterans with Hepatitis C Virus Infection.
Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco
BJ. Pain Med. 2012 Sep 7. doi:
10.1111/j.1526-4637.2012.01476.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22958315
A
comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B
virus, and human T-lymphotropic virus marker rates
for directed versus volunteer blood donations to the American Red Cross during
2005 to 2010. Dorsey
KA, Moritz ED, Steele WR, Eder AF, Stramer SL. Transfusion. 2012 Sep 25.
doi:
10.1111/j.1537-2995.2012.03904.x. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/23003320
A
Comparison of Enrollees Versus Non-enrollees in a Patient/Family HCV Psycho-education
Study. Pollio DE, North CS, Hudson AM, Hong
BA. J Clin Psychol
Med Settings. 2012 Sep 19. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22990747
Liver
Cancer
Effect
of type 2 diabetes on risk for malignancies included hepatocellular carcinoma
in chronic hepatitis C. Arase
Y, Kobayashi M, Suzuki F, et al. Hepatology. 2012 Sep 18. doi:
10.1002/hep.26087. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22991257
Deficiency
of the promyelocytic leukemia protein fosters
hepatitis C-associated hepato-carcinogenesis in mice.
Herzer K, Carbow A, Sydor S, et al. PLoS One.
2012;7(9):e44474. Epub 2012
Sep 11.
http://www.ncbi.nlm.nih.gov/pubmed/22984515
Recent Trends of Japanese Hepatocellular Carcinoma
due to HCV in Aging Society. Hiraoka A, Hidaka S,
Shimizu Y, et al. Hepatogastroenterology. 2012 Sep;59(118):1893-5.
doi: 10.5754/hge11732.
http://www.ncbi.nlm.nih.gov/pubmed/22193439
A Comparative Analysis of Hepatocellular Carcinoma
after Hepatic Resection in Young versus Elderly Patients.
Lee CR, Lim JH,
Kim SH, et al. J Gastrointest Surg. 2012 Sep;16(9):1736-43. Epub 2012 Jul 19.